

# Lexaria Bioscience Corp

14:10 14 Aug 2019

## Lexaria Bioscience taps a former Altria Group executive to join its board of directors

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the biotechnology company behind the drug delivery system DehydraTECH, tapped a new director on Wednesday who recently left one of its major business partners.

The company announced that Brian Quigley, a 16-year veteran of Altria Group, would be joining its board. Quigley spent a combined 7 years as CEO of Altria's subsidiaries US Smokeless Tobacco and then Nu-Mark, while an investment deal between the tobacco giant and Lexaria was being negotiated.

In June, the companies announced that Altria would invest up to \$12 million to fund a research and development program focused on using Lexaria's technology to develop a safer way to ingest nicotine.

READ: Lexaria Bioscience secures cannabis R&D license from Health Canada At Altria, Quigley oversaw regulatory environments for new and nicotine products and worked to implement harm reduction strategies.

In March, Quigley left Altria to co-found Green Sky Strategy, a cannabis-centric strategic advisory company. All told, he has 20 years of consumer packaged goods experience over his career.

"Lexaria continues to build towards its role as one of the world's leading reduced harm nicotine delivery companies, and we welcome Brian's expertise," Chairman Chris Bunka said in a statement.

"His years of regulatory, product launch and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world."

Lexaria's DehydraTECH system works by helping the body absorb compounds faster and more effectively.

The company's shares declined 4.5% to C\$1.06 and 5.9% \$US0.80 on OTC Markets.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

**Price:** \$0.94

**Market Cap:** \$73.92 m

### 1 Year Share Price Graph



September 2018 March 2019 September 2019

### Share Information

**Code:** LXX

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	2.8	0.83

**Sector:** Cannabis

**Website:** [www.lexariabioscience.com](http://www.lexariabioscience.com)

### Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).